Polyprenols and Alzheimer (preclinical studies)
The study was conducted in rats in the conditions of the experimentally created model of dementia of the Alzheimer type. When a polyprenolic preparation was introduced, the animals completely restored the disordered capacity for the non-spatial and spatial types of learning. As a result, it was concluded that it was possible to clinically study the action of polyprenolic preparations with the purpose of their further use in the therapy of cognitive disorders, dementias of different genesis, including those of the Alzheimer type.
Solagran Limited, Melbourne, Australia,
2 I.P. Pavlov Institute of Physiology of the Russian Academy of Sciences, Saint Petersburg, Russia
3 S.M. Kirov Academy of Forestry Engineering in Saint Petersburg, Saint Petersburg, Russia
I.M. Sechenov Institute of Evolutionary Physiology and Biochemistry of the Russian Academy of Sciences, Saint Petersburg, Russia
Currently, search and development of new approaches and preparations for the pharmacotherapy of dementias of different genesis, including those of the Alzheimer type, are of interest. In that regard, it is very important to study the possibility of use of pharmacological medications of plant origin. Here belong preparations made of conifer needles — a polyprenolic preparation (PP) and Bioeffektiv® A that contain natural biologically effective compounds that are actively involved in the mechanisms of many important physiological processes of the body.
The purpose was to study the effects of long term use of pharmacological medications of plant origin – the preparations of PP and Bioeffektiv® A – on the cognitive status in male rats on the model of dementia of the Alzheimer type.
The experiment was conducted on male rats of the Wistar line. Dementia was modelled in male rats by means of surgery, opening the brain case, and intracerebral introduction of amyloid beta into the fourth ventricle of the brain. The preparations were administered orally: PP in the therapeutic dose of 144.0 mg/day for a person (the dose of 8.6 mg/kg), Bioeffektiv® A in therapeutic dose of 960.0 mg/day (the dose of 82.0 mg/kg). The course of treatment with the preparations was 28 days. To assess the processes of learning and memory, a model of conditioned passive-avoidance response (CPAR) and Morris water test were used, as well as the behavior in the "open field" test was evaluated.
The results of the experiments evidence that, when PP is introduced to males rats in the conditions of experimentally created model of dementia, the impaired capacity of the animals for the non-spatial and spatial types of learning is fully restored. Unlike the polyprenolic preparation, Bioeffektiv® A in rats in the experiment had no positive impact on both types of learning.
Thus, a conclusion can be made that it is possible to clinically study the action of PP made of spruce needles of Picea abies (L.) Karst with the purpose of its further use in the therapy of cognitive disorders, dementias of different genesis, including those of the Alzheimer type. According to the data obtained, the preparation of Bioeffektiv® A cannot be recommended for further clinical study in this area. Since Bioeffektiv® A only has a stimulating effect on the overall motor activity of rats, restoring the impaired motor functions, it can be recommended in the case of motor dysfunctions and polyneuropathies of the peripheral genesis. (Published in the proceedings of the 2nd Conference of the Russian Association of Psychoneuroendocrinology (RAPNE), Moscow, 2010)
The text of the study is provided by courtesy of Solagran.